- Home
- IKT vs CNTB Comparison
IKT vs CNTB Comparison
Compare IKT & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- CNTB
- Stock Information
- Founded
- IKT 2008
- CNTB 2012
- Country
- IKT United States
- CNTB United States
- Employees
- IKT N/A
- CNTB N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- IKT Health Care
- CNTB Health Care
- Exchange
- IKT Nasdaq
- CNTB Nasdaq
- Market Cap
- IKT 140.5M
- CNTB 114.8M
- IPO Year
- IKT 2020
- CNTB 2021
- Fundamental
- Price
- IKT $1.66
- CNTB $1.82
- Analyst Decision
- IKT Buy
- CNTB Strong Buy
- Analyst Count
- IKT 2
- CNTB 2
- Target Price
- IKT $8.00
- CNTB $7.50
- AVG Volume (30 Days)
- IKT 97.5K
- CNTB 239.7K
- Earning Date
- IKT 08-14-2025
- CNTB 09-05-2025
- Dividend Yield
- IKT N/A
- CNTB N/A
- EPS Growth
- IKT N/A
- CNTB N/A
- EPS
- IKT N/A
- CNTB N/A
- Revenue
- IKT N/A
- CNTB $1,965,000.00
- Revenue This Year
- IKT N/A
- CNTB N/A
- Revenue Next Year
- IKT N/A
- CNTB N/A
- P/E Ratio
- IKT N/A
- CNTB N/A
- Revenue Growth
- IKT N/A
- CNTB N/A
- 52 Week Low
- IKT $1.12
- CNTB $1.63
- 52 Week High
- IKT $4.20
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- IKT 45.73
- CNTB 48.05
- Support Level
- IKT $1.66
- CNTB $1.63
- Resistance Level
- IKT $1.87
- CNTB $2.20
- Average True Range (ATR)
- IKT 0.10
- CNTB 0.20
- MACD
- IKT -0.01
- CNTB -0.02
- Stochastic Oscillator
- IKT 33.82
- CNTB 36.15
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.